Active, not recruitingPhase 4NCT05164055
Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)
Studying Glycogen storage disease due to acid maltase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genzyme, a Sanofi Company
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- Avalglucosidase alfa (GZ402666)(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2022 – 2026
Study locations (11)
- Investigational Site Number : 2500004, Bordeaux, France
- Investigational Site Number : 2500005, Brest, France
- Investigational Site Number : 2500008, Clermont-Ferrand, France
- Investigational Site Number : 2500009, Lille, France
- Investigational Site Number : 2500003, Lyon, France
- Investigational Site Number : 2500001, Marseille, France
- Investigational Site Number : 2500006, Nantes, France
- Investigational Site Number : 2500007, Nice, France
- Investigational Site Number : 2500002, Paris, France
- Investigational Site Number : 2500010, Paris, France
- Investigational Site Number : 2500011, Tours, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05164055 on ClinicalTrials.govOther trials for Glycogen storage disease due to acid maltase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07478172Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseUniversity of Missouri-Columbia
- RECRUITINGPHASE1, PHASE2NCT07282847A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)AskBio Inc
- RECRUITINGPHASE2NCT07123155Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)Shionogi
- RECRUITINGPHASE4NCT06666413China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDGenzyme, a Sanofi Company
- RECRUITINGNCT06795152Rare Glycogen Storage Diseases Natural History StudyDuke University
- RECRUITINGPHASE1, PHASE2NCT06391736Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy DrugGeneCradle Inc
- RECRUITINGNCT06121011A Global Prospective Observational Registry of Patients With Pompe DiseaseAmicus Therapeutics
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06109948Study to Assess the Safety, Tolerability, PK and PD of ABX1100Aro Biotherapeutics
See all trials for Glycogen storage disease due to acid maltase deficiency →